Selegiline Patch for Treatment of Nicotine Dependence

Status Completed

Clinical Trial Summary

Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.

Clinical Trial Description

Most smokers relapse following smoking cessation treatment. More effective smoking cessation therapies are needed to prevent the high rates of relapse. Selegiline is a selective inhibitor of monoamine oxidase B (MAO B) and has been used clinically in combination with levodopa to treat Parkinson's disease. Selegiline permits the stabilization of dopamine (DA) levels in the brain by preventing the rapid degradation of DA by means of MAO B and is used as an adjunct to levodopa therapy causing a dose-sparing effect and enhancing dopaminergic transmission. Selegiline's effect on MAO B and the resulting effect on brain DA has interesting implications for the treatment of nicotine dependence because brain DA systems may play a key role in the mediation of reward learning behavior. Previous research suggests that the brains of living smokers show a 40% decrease in the level of MAO B relative to nonsmokers or former smokers. The purpose of this study is examine whether selegiline, administered in the form of a skin patch, is effective for smoking cessation.

Participants will be randomly assigned to one of two treatments: 1) transdermal selegiline patch (STS) or 2) placebo. Treatment with STS or placebo will be given for a period of 8 weeks. Participants will be stratified by gender to evaluate the role that gender plays in moderating smoking cessation treatment. Study visits will take place once each week for 30 to 45 minutes, and will include adverse events monitoring, biochemical verification of smoking status, and a physical exam. Follow-up visits will occur at Weeks 24 and 52 to determine response to treatment. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Tobacco Use Disorder

Clinical Trial Details

NCT number	NCT01330030
Study type	Interventional
Source	Stanford University
Contact
Status	Completed
Phase	Phase 2
Start date	July 2005
Completion date	July 2011

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02432066` - Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions	Phase 2
Completed	`NCT03960138` - Examining the Effects of Neural Stimulation on Inhibitory Control and Cigarette Smoking	N/A
Recruiting	`NCT05030272` - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings	N/A
Completed	`NCT04646668` - Comparative Abuse Liability Among African American and White Smokers	N/A
Completed	`NCT02560324` - Effect of Ramelteon on Smoking Abstinence	Phase 2
Completed	`NCT02347605` - Medicinal Nicotine for Preventing Cue Induced Craving	N/A
Completed	`NCT01428310` - Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke	Phase 1
Completed	`NCT01570595` - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV	Phase 1/Phase 2
Terminated	`NCT01800500` - Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers	N/A
Completed	`NCT01625767` - Tobacco Approach Avoidance Training for Adolescent Smokers-1	Phase 2
Completed	`NCT01442753` - Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth	N/A
Active, not recruiting	`NCT01539525` - Screening to Augment Referral to Treatment- Project START	Phase 2
Completed	`NCT01337817` - A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers	Phase 1
Completed	`NCT00967005` - N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers	Phase 2
Active, not recruiting	`NCT00751660` - Screening Methods in Finding Lung Cancer Early in Current or Former Smokers	N/A
Completed	`NCT00790569` - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking	N/A
Completed	`NCT00664261` - Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking	N/A
Completed	`NCT01213524` - Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia	Phase 2
Completed	`NCT00218179` - Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1	N/A
Completed	`NCT00134927` - A Survey on Consumer Use of Over-the-Counter (OTC) Nicotine Patches	N/A